Profile data is unavailable for this security.
About the company
Biotage AB is a Sweden-based company that develops and sells systems, consumables and services in the field of life sciences. Its customers include pharmaceutical and biotechnology companies, companies within the food industry and academic institutions. The Company offers systems and services within three areas: analytical chemistry, organic chemistry and industrial resins. Biotage’s offering within analytical chemistry consists of consumables with related applications to extract selected substances from various types of samples. The Company’s offering within organic chemistry includes products for pharmaceutical development based on both small molecules and peptides and its offering within industrial resins is composed of polymer-based resins and research services that lead to the development and manufacture of polymer-based materials. As of December 31, 2013, the Company operated 12 wholly owned subsidiaries worldwide.
- Revenue in SEK (TTM)1.98bn
- Net income in SEK236.00m
- Incorporated1997
- Employees669.00
- LocationBiotage ABVimpelgatan 5UPPSALA 753 18SwedenSWE
- Phone+46 18565900
- Fax+46 18591922
- Websitehttps://www.biotage.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BICO Group AB | 2.26bn | -1.61bn | 3.07bn | 837.00 | -- | 1.03 | -- | 1.36 | -22.34 | -26.39 | 31.73 | 42.97 | 0.3398 | 2.33 | 4.14 | 2,555,996.00 | -24.19 | -- | -27.59 | -- | 50.48 | -- | -71.20 | -- | 1.95 | -13.81 | 0.3933 | -- | 6.09 | -- | -1,889.33 | -- | -- | -- |
| Medistim ASA | 526.32m | 101.65m | 3.07bn | 152.00 | 30.16 | 7.20 | 24.45 | 5.84 | 5.60 | 5.60 | 29.01 | 23.48 | 1.03 | 0.7765 | 6.15 | 3,492,704.00 | 19.95 | 22.93 | 24.07 | 28.52 | 79.02 | 78.25 | 19.31 | 20.64 | 2.99 | -- | 0.0206 | 75.25 | 7.00 | 10.06 | -8.91 | 12.72 | 0.033 | 14.87 |
| Detection Technology Oyj | -1.14tn | -1.14tn | 3.11bn | 478.00 | -- | 3.75 | -- | -- | -- | -- | -- | 4.97 | -- | -- | -- | -- | -- | 9.34 | -- | 11.96 | -- | 47.44 | -- | 8.22 | 3.13 | -- | 0.081 | 53.45 | 5.29 | 2.02 | 7.55 | -18.03 | -14.88 | -9.55 |
| RaySearch Laboratories AB (publ) | 1.05bn | 100.71m | 3.82bn | 398.00 | 48.80 | 6.33 | 9.76 | 3.64 | 2.94 | 2.94 | 30.64 | 22.65 | 0.5313 | 5.65 | 2.97 | 2,697,136.00 | 5.10 | 1.29 | 7.80 | 1.88 | 89.92 | 90.57 | 9.60 | 2.55 | 1.19 | 47.17 | 0.4036 | 69.00 | 21.16 | 10.26 | 243.06 | 0.7648 | -1.31 | -- |
| CellaVision AB | 708.28m | 141.22m | 5.94bn | 223.00 | 42.06 | 7.83 | 32.65 | 8.39 | 5.92 | 5.92 | 29.69 | 31.81 | 0.757 | 1.68 | 8.45 | 3,106,469.00 | 15.09 | 15.30 | 17.34 | 18.24 | 67.52 | 69.03 | 19.94 | 19.98 | 2.21 | 66.29 | 0.0688 | 110.18 | 5.94 | 13.17 | 10.12 | 8.00 | 30.45 | 8.45 |
| Surgical Science Sweden AB | 842.02m | 207.95m | 6.17bn | 265.00 | 29.68 | 1.35 | 23.31 | 7.33 | 4.08 | 4.08 | 16.51 | 89.92 | 0.1749 | 1.68 | 6.12 | 3,238,531.00 | 4.32 | 4.49 | 4.59 | 4.78 | 68.59 | 70.06 | 24.70 | 23.75 | 3.53 | -- | 0.00 | 0.00 | 10.01 | 68.14 | 24.47 | -- | 38.57 | -- |
| Revenio Group Oyj | 1.10bn | 216.10m | 8.27bn | 216.00 | 37.86 | 7.26 | 31.71 | 7.53 | 0.7205 | 0.7205 | 3.66 | 3.76 | 0.7069 | 5.50 | 7.60 | 447,574.10 | 13.90 | 14.33 | 16.77 | 17.90 | 51.01 | 50.73 | 19.66 | 21.13 | 1.79 | 28.49 | 0.1521 | 55.81 | -0.4125 | 25.80 | -12.15 | 18.72 | 17.67 | 6.30 |
| ChemoMetec A/S | 612.00m | 219.17m | 9.20bn | 171.00 | 41.98 | 12.10 | 37.21 | 15.03 | 8.26 | 8.26 | 23.07 | 28.66 | 0.6982 | 0.8064 | 6.01 | 2,448,421.00 | 25.00 | 30.43 | 29.69 | 38.99 | 78.85 | 79.44 | 35.81 | 34.17 | 3.37 | -- | 0.0118 | 46.90 | 3.74 | 31.58 | 12.04 | 57.88 | 19.91 | -- |
| Arjo AB (publ) | 11.10bn | 518.00m | 10.35bn | 6.71k | 21.41 | 1.37 | 6.68 | 0.9323 | 1.90 | 1.90 | 40.76 | 29.72 | 0.6911 | 4.15 | 6.31 | 1,632,980.00 | 3.21 | 3.55 | 4.44 | 5.55 | 43.43 | 44.01 | 4.64 | 5.41 | 0.6913 | 4.14 | 0.4024 | 43.01 | 10.03 | 5.97 | 6.90 | 10.15 | -8.89 | 10.35 |
| Biotage AB | 1.98bn | 236.00m | 12.81bn | 669.00 | 53.18 | 3.29 | 31.78 | 6.47 | 3.01 | 3.01 | 25.57 | 48.61 | 0.5276 | 2.01 | 7.78 | 2,939,169.00 | 6.29 | 10.74 | 7.33 | 12.77 | 62.19 | 61.34 | 11.91 | 15.77 | 1.52 | 8.95 | 0.062 | 40.11 | 18.90 | 15.37 | -8.21 | 7.97 | 14.05 | 1.30 |
| Xvivo Perfusion AB | 642.95m | 100.43m | 12.85bn | 148.00 | 123.00 | 6.42 | 77.96 | 19.99 | 3.32 | 3.32 | 21.18 | 63.59 | 0.322 | 1.28 | 4.27 | 4,018,431.00 | 5.03 | 1.24 | 5.49 | 1.33 | 73.94 | 73.14 | 15.62 | 4.76 | 3.40 | -- | 0.0152 | 0.00 | 43.88 | 26.04 | 398.29 | 48.57 | 21.35 | -- |
Data as of Jul 03 2024. Currency figures normalised to Biotage AB's reporting currency: Swedish Krona SEK
39.13%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Didner & Gerge Fonder ABas of 31 Dec 2023 | 5.35m | 6.69% |
| SEB Investment Management ABas of 31 May 2024 | 4.67m | 5.84% |
| Invesco Advisers, Inc.as of 31 May 2024 | 3.34m | 4.18% |
| Handelsbanken Fonder ABas of 31 Dec 2023 | 3.25m | 4.07% |
| Fj�rde AP-fondenas of 31 Dec 2023 | 2.77m | 3.46% |
| Swedbank Robur Fonder ABas of 31 Dec 2023 | 2.60m | 3.25% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 2.55m | 3.19% |
| F�rsta AP-fondenas of 31 Dec 2023 | 2.50m | 3.13% |
| Tredje AP-fondenas of 31 Dec 2023 | 2.25m | 2.81% |
| The Vanguard Group, Inc.as of 06 Jun 2024 | 2.02m | 2.53% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
